Oncolytic virus · Kills target cells · developed by Krystal Biotech
KB707 is an oncolytic herpes simplex virus type 1 engineered to express the immunostimulatory cytokines IL-2 and IL-12. After intratumoral administration it replicates in tumor cells, causing their lysis and releasing tumor antigens that stimulate a cytotoxic T-lymphocyte response. It is studied in melanoma and cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05970497 | Phase 1/2 | Cancer | Recruiting | KRYS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CancerCutaneous MelanomaMelanoma Stage IIIMelanoma Stage IV
Updated Oct 18, 2026. Something wrong or missing? Report it on the KRYS page.
See KRYS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KRYS catalysts and pipeline →